Pfizer Lines Up European Pegfilgrastim
Receives CHMP Nod For Nyvepria Version Following US Approval
Pfizer has received an endorsement for a pan-European marketing authorization for its Nyvepria pegfilgrastim biosimilar from the EMA’s CHMP. However, the company would not be drawn on commercialization plans amid competition from numerous other approved versions.
